EU Reforms Offer Mixed Blessings For Generics And Biosimilars
Changes To Regulatory Data Protection And Faster, Simpler Authorization Procedures
A long-awaited package of European pharmaceutical legislation reforms unveiled by the European Commission contains a number of measures that will affect the generics and biosimilars industry – including changes to regulatory data protection periods, simplified marketing authorization procedures, and moves towards greater digitalization.
